Get the Stockscreener App
1.13
2.59%
-0.03
After Hours:
1.12
-0.010
-0.88%
Biovie Inc stock is traded at $1.13, with a volume of 166.81K.
It is down -2.59% in the last 24 hours and down -35.43% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$1.16
Open:
$1.18
24h Volume:
166.81K
Relative Volume:
0.87
Market Cap:
$9.81M
Revenue:
Net Income/Loss:
$-19.92M
P/E Ratio:
-0.2645
EPS:
-4.2716
Net Cash Flow:
$-20.51M
1W Performance:
-11.72%
1M Performance:
-35.43%
6M Performance:
-19.86%
1Y Performance:
-42.35%
1-Day Range:
$1.13
$1.19
1-Week Range:
$1.13
$1.4412
52-Week Range:
$0.82
$3.79
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
1.13 | 9.81M | 0 | -19.92M | -20.51M | -4.2716 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
BioVie Warrant (BIVIW) Holds Steady at $0.30 as Traders Eye Narrow RangeUnusual Put Volume - https://www.dars.gov.et/
BIVIBioVie Inc. | News - OTC Markets
BioVie (BIVI) Stock Analysis Report | Financials & Insights - Benzinga
Form 8K Biovie Inc For: 14 September By Investing.com - Investing.com UK
BIVI 8-K FilingsBioVie, Inc. SEC 8-K - Stock Titan
How much new stock can BioVie (NASDAQ: BIVI) now sell into the market? - Stock Titan
Biovie seeks FDA meeting to plan Phase 3 trial for Parkinson’s drug candidate - parkinsonsnewstoday.com
Jane Street Group Expands BioVie Inc (BIVI) Stake by Over 1,100% - GuruFocus
BioVie advances bezisterim Phase 3 Parkinson’s trial - grafa.com
Market movers: Novartis, Qualcomm, EchoStar, BioVie... - proactiveinvestors.com
Market movers: Novartis, Qualcomm, EchoStar, BioVie... - proactiveinvestors.com.au
BioVie advances Parkinson’s Phase 3 trial plans after positive Phase 2 results and FDA engagement. - Pluang
BioVie advances Parkinson’s Phase 3 development program with FDA engagement - Yahoo Finance
BioVie Announces Update to Parkinson’s Phase 3 Development Program - markets.businessinsider.com
BioVie seeks FDA feedback on a proposed Parkinson’s trial of about 175 patients. - Stock Titan
BioVie advances Parkinson’s Phase 3 development program with FDA engagement - Proactive financial news
BIVI Form 4 FilingsBioVie, Inc. SEC Form 4 - Stock Titan
Jane Street reports over 5% stake in BioVie (BIVI) - Stock Titan
Small cap wrap: Alvopetro, Royal Road Minerals, Nextech3D.ai, TNR Gold... - Proactive financial news
Market movers: PG&E, Aon, Eli Lilly, BioVie... - Proactive financial news
BioVie completes final patient visit in Phase 2 Long COVID trial, topline results due by September 2026 - Pluang
BioVie (BIVI) Completes Final Visit in ADDRESS-LC Phase 2 Trial for Long COVID Neurological Symptoms - GuruFocus
BioVie Announces Completion of Treatment Phase of - GlobeNewswire
Dow falls as US strikes Iran, rate-hike bets jump - proactiveinvestors.co.uk
BioVie completes final patient visit in Phase 2 Long COVID trial - Proactive financial news
Price to earnings forward of BioVie Inc. – BOATS:BIVIW - TradingView
Biovie CFO Joanne Kim buys $5,450 in Biovie Inc. stock By Investing.com - Investing.com Australia
Biovie CFO Joanne Kim buys $5,450 in Biovie Inc. stock By Investing.com - Investing.com Nigeria
Insider Stock Purchases: August 29, 2026 - Moomoo
BioVie Stock (BIVI) Opinions on Phase 2 Trial Results - Quiver Quantitative
BioVie Inc. CEO Cuong V Do buys $31,636 in company stock - Investing.com India
Biovie director Amy Chappell acquires $1,570 in BIVI common stock By Investing.com - Investing.com India
BioVie Inc (BIVI) Chief Medical Officer Joseph Palumbo Buys 4,84 - GuruFocus
Biovie CMO Joseph Palumbo buys $10,460 in common stock By Investing.com - Investing.com Canada
Biovie CFO Joanne Kim buys $5,450 in Biovie Inc. stock By Investing.com - Investing.com India
BioVie Stock (BIVI) Opinions on Phase 2 Trial Results - Quiver Quantitative
Biovie director Amy Chappell acquires $1,570 in BIVI common stock By Investing.com - Investing.com UK
Biovie CMO Joseph Palumbo buys $10,460 in common stock By Investing.com - Investing.com India
BioVie (NASDAQ: BIVI) CMO boosts stake with open-market share buy - Stock Titan
Biovie director Amy Chappell acquires $1,570 in BIVI common stock By Investing.com - Investing.com Canada
Biovie CMO Joseph Palumbo buys $10,460 in common stock By Investing.com - Investing.com UK
Biovie CFO Joanne Kim buys $5,450 in Biovie Inc. stock - Investing.com
Biovie CFO Joanne Kim buys $5,450 in Biovie Inc. stock By Investing.com - Investing.com Canada
BioVie Inc. CEO Cuong V Do buys $31,636 in company stock - Investing.com UK
Biovie CFO Joanne Kim buys $5,450 in Biovie Inc. stock By Investing.com - Investing.com UK
Biovie director Amy Chappell acquires $1,570 in BIVI common stock - Investing.com
BioVie (BIVI) CEO makes 15,210-share open-market buy - Stock Titan
BioVie Inc. CEO Cuong V Do buys $31,636 in company stock - Investing.com
Biovie CMO Joseph Palumbo buys $10,460 in common stock - Investing.com
BioVie (BIVI) director makes open-market share purchase - Stock Titan
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biovie Inc Stock (BIVI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chappell Amy Suzon | Director |
Aug 28 '26 |
Buy |
2.16 |
727 |
1,570 |
727 |
| KIM JOANNE WENDY | Chief Financial Officer |
Aug 28 '26 |
Buy |
2.18 |
2,500 |
5,450 |
3,441 |
| DO CUONG V | President & CEO |
Aug 27 '26 |
Buy |
2.08 |
15,210 |
31,637 |
16,117 |
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):